Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
21.74
-0.11 (-0.50%)
Oct 9, 2026, 3:04 PM CST
Jiangsu Nhwa Pharmaceutical Co., LTD Employees
Jiangsu Nhwa Pharmaceutical Co., LTD had 6,003 employees as of December 31, 2025. The number of employees increased by 80 or 1.35% compared to the previous year. That makes Jiangsu Nhwa Pharmaceutical Co., LTD the 4,932nd largest employer in the world and 821st in China.
Employees
6,003
Change (1Y)
80
Growth (1Y)
1.35%
Revenue / Employee
1.02M CNY
Profits / Employee
182.83K CNY
Market Cap
22.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,003 | 80 | 1.35% |
| Dec 31, 2024 | 5,923 | 529 | 9.81% |
| Dec 31, 2023 | 5,394 | 439 | 8.86% |
| Jan 1, 2023 | 4,955 | 223 | 4.71% |
| Jan 1, 2022 | 4,732 | 281 | 6.31% |
| Dec 31, 2020 | 4,451 | 37 | 0.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shijiazhuang Yiling Pharmaceutical | 11,343 |
| Tasly Pharmaceutical Group | 10,563 |
| Livzon Pharmaceutical Group | 8,878 |
| Zhejiang Huahai Pharmaceutical | 8,797 |
| Shanghai Haoyuan Chemexpress | 4,540 |
| Hubei Jumpcan Pharmaceutical | 4,137 |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 3,890 |
| Walvax Biotechnology | 1,981 |
Jiangsu Nhwa Pharmaceutical Co., LTD News
- 7 weeks ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: H1 2026 - Filings
- 5 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Annual report: H2 2025 - Filings
- 5 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: Q1 2026 - Filings
- 9 months ago - Luye Pharma Grants Nhwa Rights To Commercialize Three LAI Antipsychotics In Chinese Mainland - Nasdaq
- 11 months ago - Jiangsu Nhwa Pharmaceutical Co., LTD Quarterly report: Q3 2025 - Filings